BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 20184589)

  • 1. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
    Califf RM; Boolell M; Haffner SM; Bethel M; McMurray J; Duggal A; Holman RR;
    Am Heart J; 2008 Oct; 156(4):623-32. PubMed ID: 18946890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Latini R; Staszewsky L; Sun JL; Bethel MA; Disertori M; Haffner SM; Holman RR; Chang F; Giles TD; Maggioni AP; Rutten GE; Standl E; Thomas L; Tognoni G; Califf RM; McMurray JJ
    Am Heart J; 2013 Nov; 166(5):935-40.e1. PubMed ID: 24176451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
    Wong YW; Thomas L; Sun JL; McMurray JJ; Krum H; Hernandez AF; Rutten GE; Leiter LA; Standl E; Haffner SM; Mazzone T; Martinez FA; Tognoni G; Giles T; Califf RM
    Circ Heart Fail; 2013 Mar; 6(2):203-10. PubMed ID: 23388113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [NAVIGATOR: A trial of prevention of cardiovascular complications and type 2 diabetes with valsartan and/or nateglinide].
    Scheen AJ
    Rev Med Liege; 2010 Apr; 65(4):217-23. PubMed ID: 20499825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
    Preiss D; Giles TD; Thomas LE; Sun JL; Haffner SM; Holman RR; Standl E; Mazzone T; Rutten GE; Tognoni G; Chiang FT; McMurray JJ; Califf RM
    Stroke; 2013 Sep; 44(9):2590-3. PubMed ID: 23899915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of renin-angiotensin system blockade in patients with diabetes mellitus.
    Braga MF; Leiter LA
    Am J Cardiol; 2009 Sep; 104(6):835-9. PubMed ID: 19733720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
    Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
    Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial.
    Harumi Higuchi Dos Santos M; Sharma A; Sun JL; Pieper K; McMurray JJ; Holman RR; Lopes RD
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28087508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
    Shen L; Shah BR; Reyes EM; Thomas L; Wojdyla D; Diem P; Leiter LA; Charbonnel B; Mareev V; Horton ES; Haffner SM; Soska V; Holman R; Bethel MA; Schaper F; Sun JL; McMurray JJ; Califf RM; Krum H
    BMJ; 2013 Dec; 347():f6745. PubMed ID: 24322398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of valsartan on the incidence of diabetes and cardiovascular events.
    ; McMurray JJ; Holman RR; Haffner SM; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
    N Engl J Med; 2010 Apr; 362(16):1477-90. PubMed ID: 20228403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome.
    Deedwania PC; Schmieder R
    J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7 Suppl 1():S12-8. PubMed ID: 16986230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Navigating the choices for diabetes prevention.
    Nathan DM
    N Engl J Med; 2010 Apr; 362(16):1533-5. PubMed ID: 20228400
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
    Aksnes TA; Kjeldsen SE; Rostrup M; Störset O; Hua TA; Julius S
    J Hum Hypertens; 2008 Aug; 22(8):520-7. PubMed ID: 18509347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. People with impaired glucose tolerance and impaired fasting glucose are similarly susceptible to cardiovascular disease: a study in first-degree relatives of type 2 diabetic patients.
    Amini M; Horri N; Zare M; Haghighi S; Hosseini SM; Aminorroaya A; Hovsepian S
    Ann Nutr Metab; 2010; 56(4):267-72. PubMed ID: 20413967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of nateglinide on the incidence of diabetes and cardiovascular events.
    ; Holman RR; Haffner SM; McMurray JJ; Bethel MA; Holzhauer B; Hua TA; Belenkov Y; Boolell M; Buse JB; Buckley BM; Chacra AR; Chiang FT; Charbonnel B; Chow CC; Davies MJ; Deedwania P; Diem P; Einhorn D; Fonseca V; Fulcher GR; Gaciong Z; Gaztambide S; Giles T; Horton E; Ilkova H; Jenssen T; Kahn SE; Krum H; Laakso M; Leiter LA; Levitt NS; Mareev V; Martinez F; Masson C; Mazzone T; Meaney E; Nesto R; Pan C; Prager R; Raptis SA; Rutten GE; Sandstroem H; Schaper F; Scheen A; Schmitz O; Sinay I; Soska V; Stender S; Tamás G; Tognoni G; Tuomilehto J; Villamil AS; Vozár J; Califf RM
    N Engl J Med; 2010 Apr; 362(16):1463-76. PubMed ID: 20228402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
    Chatterjee R; Thomas L; Svetkey L; Brancati FL; Califf RM; Edelman D
    Am J Hypertens; 2013 Jun; 26(6):723-6. PubMed ID: 23417031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score.
    Tuomilehto J; Lindström J; Hellmich M; Lehmacher W; Westermeier T; Evers T; Brückner A; Peltonen M; Qiao Q; Chiasson JL
    Diabetes Res Clin Pract; 2010 Feb; 87(2):267-74. PubMed ID: 20022651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study.
    Gokulakrishnan K; Deepa R; Mohan V; Gross MD
    Metabolism; 2006 Feb; 55(2):237-42. PubMed ID: 16423632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.